Bayer to Advance Two First-of-its-Kind Investigational Cell and Gene Therapies for Parkinson’s Disease
In parallel a gene therapy investigational program also targeted at providing advanced therapies for Parkinsons disease is driven forward by Bayers wholly-owned clinical-stage adeno-associated virus (AAV) gene therapy company Asklepios BioPharmaceutical Inc. (AskBio).
- In parallel a gene therapy investigational program also targeted at providing advanced therapies for Parkinsons disease is driven forward by Bayers wholly-owned clinical-stage adeno-associated virus (AAV) gene therapy company Asklepios BioPharmaceutical Inc. (AskBio).
- The potential of BlueRock and AskBios clinical candidates to treat Parkinsons disease and truly help patients with their high unmet medical need could be immense, said Wolfram Carius, Head of Cell and Gene Therapy at Bayer.
- Parkinsons disease is the most common neurodegenerative movement disorder, impacting more than 10 million people worldwide.
- By targeting the disease at its root cause, cell and gene therapies aim to go beyond symptomatic treatments.